Legal & General Group Plc lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,116 shares of the biopharmaceutical company’s stock after acquiring an additional 5,585 shares during the period. Legal & General Group Plc’s holdings in Halozyme Therapeutics were worth $567,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of HALO. BlackRock Inc. lifted its stake in Halozyme Therapeutics by 7,292.8% in the 1st quarter. BlackRock Inc. now owns 11,062,842 shares of the biopharmaceutical company’s stock valued at $143,374,000 after purchasing an additional 10,913,199 shares during the last quarter. Granite Investment Partners LLC bought a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $7,250,000. Bank of New York Mellon Corp lifted its stake in Halozyme Therapeutics by 27.3% in the 1st quarter. Bank of New York Mellon Corp now owns 1,806,490 shares of the biopharmaceutical company’s stock valued at $23,412,000 after purchasing an additional 387,486 shares during the last quarter. Vanguard Group Inc. lifted its stake in Halozyme Therapeutics by 3.7% in the 1st quarter. Vanguard Group Inc. now owns 8,763,558 shares of the biopharmaceutical company’s stock valued at $113,576,000 after purchasing an additional 311,215 shares during the last quarter. Finally, Rubric Capital Management LP bought a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $3,846,000. 85.06% of the stock is owned by institutional investors.

Several equities analysts recently commented on the stock. BidaskClub downgraded shares of Halozyme Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Friday, August 11th. Canaccord Genuity set a $16.00 price objective on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 26th. Jefferies Group LLC reissued an “underperform” rating and issued a $7.00 price objective (up previously from $6.75) on shares of Halozyme Therapeutics in a research note on Thursday, August 10th. Finally, Barclays PLC reissued an “overweight” rating and issued a $16.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, June 23rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $16.63.

COPYRIGHT VIOLATION NOTICE: This article was published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/halozyme-therapeutics-inc-halo-stake-increased-by-legal-general-group-plc/1611681.html.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) opened at 17.39 on Friday. The company’s market cap is $2.33 billion. Halozyme Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $17.75. The company has a 50-day moving average of $14.60 and a 200 day moving average of $13.58.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post ($0.13) EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.